Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Launched by TANTA UNIVERSITY · Jan 2, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, ethosuximide and pentoxifylline, on abdominal pain caused by Irritable Bowel Syndrome (IBS). IBS is a common digestive disorder that can cause discomfort and pain in the stomach. The trial aims to find out if these medications can help reduce pain in people with IBS who have been experiencing moderate to severe symptoms.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of IBS as defined by specific guidelines. They should have been experiencing an average pain level of 4 or higher on a scale from 0 to 10 in the week leading up to their visit. It’s important that their IBS treatment has been stable for at least a month before joining the study. However, people who are pregnant or breastfeeding, have certain health conditions like severe liver or kidney issues, or are taking specific medications will not be able to participate. Those who join the trial can expect to receive careful monitoring and support throughout the study as researchers gather information on how well the medications work for managing their IBS-related abdominal pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Age ≥ 18 years,
• • Man and Women, Negative pregnancy test and effective contraception,
• • IBS defined by the Rome criteria IV
• • During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.
• • IBS Treatment stable for 1 month
• Exclusion Criteria:
• • • Breastfeeding
• • Diabetic patients
• • Significant liver function abnormalities (transaminases\> 3N, cholestasis) and moderate renal disease (MDRD \<60 ml / min)
• • Addiction to alcohol and / or drugs,
• • Antiepileptic drugs taken (epilepsy or chronic pain)
• • Chronic pain of greater intensity than that related to IBS,
• • Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.
• • History or current severe depression (hospitalization, long-term antidepressant treatment)
• • Psychotic disorders,